[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, Villa E: The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer; 2010 May 1;116(9):2208-14
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
  • BACKGROUND: Biliary tract adenocarcinoma (BTA) is an uncommon tumor with a poor prognosis and no standard, systemic chemotherapy.
  • The combined cisplatin, epirubicin, 5-fluorouracil, and gemcitabine (PEFG) regimen is an effective, upfront treatment for advanced pancreatic cancer.
  • METHODS: PEFG (cisplatin 40 mg/m(2) and epirubicin 40 mg/m(2) on Day 1; gemcitabine 600 mg/m(2) on Days 1 and 8; and 5-fluorouracil [FU] 200 mg/m(2) daily as a continuous infusion) was administered to chemotherapy-naive patients who had a cytologic or histologic diagnosis of locally advanced or metastatic BTA, aged <or=75 years, and a performance status (PS) >60 either until they had evidence progressive disease or for a maximum of 6 months.
  • Tumor size was assessed every 2 months during treatment.
  • Primary tumor sites were the intrahepatic bile duct in 10 patients (27%), the extrahepatic bile duct in 8 patients (22%), the gallbladder in 12 patients (32%), and the ampulla of Vater in 7 patients (19%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20187098.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Louvet C, Tournigand C: Time to move to targeted drugs in biliary tract cancer? Onkologie; 2010;33(1-2):10-1
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time to move to targeted drugs in biliary tract cancer?
  • [MeSH-major] Adenocarcinoma / drug therapy. Ampulla of Vater. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Common Bile Duct Neoplasms / drug therapy. Drug Delivery Systems / methods. Gallbladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2010;33(1-2):45-7 [20164661.001]
  • (PMID = 20164655.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Johansen SS, Karkov J: A fatal overdose of the ergot derivative cabergoline. Forensic Sci Int; 2004 Nov 10;146(1):47-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autopsy showed an extrahepatic bile duct adenocarcinoma with spread to the gall bladder, the liver, and regional lymphnodes.
  • Biological samples obtained at the autopsy were screened for common drugs and narcotics.
  • Several drugs such as buprenorphine, codeine, paracetamol, and propranolol were detected in the blood at therapeutic levels.
  • A method to determine cabergoline in whole blood and other forensic matrices was developed, and further investigations determined cabergoline concentrations in whole blood and liver tissue of 94 and 3100 microg/kg, respectively.
  • The blood concentration was 100 times above the therapeutic level reported on cabergoline in plasma and in combination with her symptoms, suggest she took a fatal overdose of cabergoline.
  • [MeSH-minor] Aged. Chromatography, Ion Exchange. Drug Overdose. Female. Gas Chromatography-Mass Spectrometry. Humans. Liver / chemistry. Molecular Structure. Parkinson Disease / drug therapy. Spectrometry, Mass, Electrospray Ionization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15485721.001).
  • [ISSN] 0379-0738
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Ergolines; LL60K9J05T / cabergoline
  •  go-up   go-down


Advertisement
4. Schoppmeyer K, Miethe S, Wiedmann M, Liebmann A, Hauss J, Mossner J, Caca K, Witzigmann H, Hildebrandt G: Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. Am J Clin Oncol; 2006 Dec;29(6):576-82
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
  • OBJECTIVE: Both radiotherapy and chemotherapy with gemcitabine and capecitabine have efficacy in biliary cancer.
  • Our aim was to determine the toxicity and efficacy of a postoperative regimen combining both treatment modalities in extrahepatic bile duct cancer.
  • METHODS: Patients were eligible after surgery for extrahepatic bile duct adenocarcinoma.
  • Surgery included resection of lymph node positive cancer, incomplete resections and diagnostic laparotomy in unresectable tumors.
  • Patients received a fractionated radiotherapy of 49.6 Gy accompanied by gemcitabine once a week.
  • The treatment continued for 6 cycles in nonmeasurable disease or until disease progression or intolerable toxicity.
  • Radiotherapy was completed in all patients and a total of 66 cycles of chemotherapy was applied.
  • CONCLUSIONS: Radiochemotherapy using gemcitabine followed by gemcitabine and capecitabine is an active regimen with manageable toxicity after resection of extrahepatic bile duct cancer but has significant toxicity in unresectable disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / radiotherapy. Bile Ducts, Extrahepatic
  • [MeSH-minor] Adult. Aged. Capecitabine. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Extrahepatic bile duct cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17148994.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Park I, Lee JL, Ryu MH, Kim TW, Chang HM, Lee SS, Sohn BS, Kim EK, Park DH, Lee SS, Suh DW, Lee SK, Kim MH, Lee J: Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. Oncology; 2009;76(2):126-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients.
  • AIM: We investigated the efficacy and safety of S-1 monotherapy for the treatment of advanced biliary tract adenocarcinoma (BTA) in a clinical practice setting.
  • METHODS: We reviewed clinical data from 217 patients with advanced BTA who were treated with S-1 monotherapy between August 2004 and September 2007.
  • The primary tumors were intrahepatic (n = 57), in the gall bladder (n = 50), in extrahepatic bile ducts (n = 41) and in the ampulla of Vater (n = 14).
  • The median time to progression was 2.7 months and the median overall survival time was 6.9 months.
  • Response rates and survival differed significantly according to the primary site of the tumor (p = 0.002 and p < 0.001, respectively), with extrahepatic bile duct adenocarcinoma having the best prognosis.
  • The treatment regimen produced only mild toxicity in most cases (grade 1 or 2), even for patients with hyperbilirubinemia.
  • The efficacy of S-1 against advanced BTA depends on the tumor site and is most effective in patients with extrahepatic BTA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biliary Tract Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Cohort Studies. Drug Combinations. Drug Delivery Systems. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158445.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


6. Matsuyama S, Takei M, Kido S, Magata S, Motoyama K, Kitahara K, Miyazaki K: [A case of para-aortic lymph node recurrence of gallbladder cancer completely responding to single drug (UFT) chemotherapy]. Gan To Kagaku Ryoho; 2003 Apr;30(4):547-9
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of para-aortic lymph node recurrence of gallbladder cancer completely responding to single drug (UFT) chemotherapy].
  • A 67-year-old man with gallbladder cancer was treated by cholecystectomy and extrahepatic bile duct resection with regional lymph node dissection.
  • Single drug chemotherapy of UFT at 400 mg was started.
  • UFT may be the primary candidate for chemotherapy for lymph node recurrence of gallbladder cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Agents / administration & dosage. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / surgery. Lymph Node Excision. Lymph Nodes / pathology. Tegafur / administration & dosage. Uracil / administration & dosage
  • [MeSH-minor] Aged. Bile Ducts, Extrahepatic / surgery. Cholecystectomy. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12722690.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


7. Zheng SS, Qin YS, Liang TB, Huang DS, Zhang M, Wang WL, Shen Y, Wang JH: [Long-term results of 84 surgically treated patients with extrahepatic bile duct carcinoma]. Zhonghua Zhong Liu Za Zhi; 2005 Sep;27(9):554-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of 84 surgically treated patients with extrahepatic bile duct carcinoma].
  • OBJECTIVE: Extrahepatic bile duct carcinoma is a rare but dismal malignacy.
  • This study is conducted to show retrospective review and analysis of the correlation between the prognosis and different treatment modalities.
  • RESULTS: Of the 84 patients, 33 had complete resection, 19 palliative resection, 12 exploration alone, and the remaining 20 were treated by chemotherapy and/or radiotherapy.
  • The mean follow-up time was 592 days.
  • The 1-, 3- and 5-year survival rate following complete resection was 76.8%, 52.6% and 30.5% respectively, which was significantly higher than those of palliative surgery or chemotherapy/radiotherapy (P < 0.01).
  • CONCLUSION: The prognosis of extrahepatic bile duct carcinoma remains poor even after complete resection as shown to have a 5-year survival of 30.5%.
  • More effective adjuvant therapy is needed.
  • Early diagnosis and early treatment is still the key to improve the long-term survival of extrahepatic bile duct carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biliary Tract Surgical Procedures / methods. Biliary Tract Surgical Procedures / mortality. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438856.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Ueno H, Ikeda M: [Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1311-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy].
  • Biliary tract cancers, including extrahepatic bile duct cancer, are often diagnosed at an advanced stage; however,no standard therapies have been established as yet for this disease,and new,effective chemotherapeutic agents are being sought.
  • Recently, a late phase II study of S-1, an oral fluoropyrimidine, in 40 patients with advanced biliary tract cancer yielded a good response rate of 35.0%.
  • In this article,we report two patients with advanced extrahepatic bile duct cancer enrolled in the study who showed a partial response to S-1 monotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Extrahepatic. Oxonic Acid / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Quality of Life

  • Genetic Alliance. consumer health - Extrahepatic bile duct cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687221.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


9. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, Saigusa N, Hayasaka A, Matsuzaki O, Miyazaki M: A case of small cell carcinoma of the common bile duct. Hepatogastroenterology; 2005 Mar-Apr;52(62):363-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small cell carcinoma of the common bile duct.
  • We report a case of small cell carcinoma which occurred in the common bile duct.
  • Computed tomography and ultrasonography showed a mass near the pancreas head and dilatation of the intrahepatic bile ducts.
  • Endoscopic nasobiliary drainage was undertaken, and it revealed obstruction of the common bile duct.
  • The patient was diagnosed preoperatively as having extrahepatic bile duct cancer.
  • Upon laparotomy, a tumor was found to be located in the middle common bile duct.
  • Postoperative pathological examination revealed well-differentiated papillary adenocarcinoma on the surface of the bile duct lumen, but a large part of the extraductal component was small cell carcinoma.
  • The patient then underwent two postoperative courses of systemic chemotherapy.
  • Nevertheless, she died of cancer recurrence eight months after the operation, which showed that the tumor had a highly lethal nature, with rapid and widespread dissemination.
  • Further therapeutic trials are needed to improve survival in such cases.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Common Bile Duct
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholangiopancreatography, Magnetic Resonance. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816436.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Aldrighetti L, Arru M, Ronzoni M, Salvioni M, Villa E, Ferla G: Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer. Hepatogastroenterology; 2001 Sep-Oct;48(41):1302-7
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer.
  • Hepatic arterial infusion of floxuridine is an effective treatment for unresectable hepatic metastases from colorectal cancer.
  • Despite its pharmacological advantage of higher tumor drug concentration with minimal systemic toxicity, hepatic arterial infusion of floxuridine is characterized by regional toxicity, including hepatobiliary damage resembling idiopathic sclerosing cholangitis (5-29% of treated cases).
  • Unlike previous reports describing biliary damage of both intrahepatic and extrahepatic ducts, a case series of extrahepatic biliary stenosis after hepatic arterial infusion with floxuridine is herein described.
  • Between September 1993 and February 1999, 54 patients received intraarterial hepatic chemotherapy based on continuous infusion of floxuridine (dose escalation 0.15-0.30 mg/kg/day for 14 days every 28 days) plus dexamethasone 28 mg.
  • Five patients (9.2%) developed biliary toxicity with jaundice and cholangitis (3 cases), alterations of liver function tests and radiological features of biliary tract abnormalities.
  • They received from 9 to 19 cycles (mean 14.5 +/- 6.3 cycles) of floxuridine infusion with a total drug delivered dose ranging from 20.3 to 41.02 mg/kg (mean: 31.4 +/- 13.5 mg/kg).
  • Extrahepatic biliary sclerosis was discovered by computed tomography scan and ultrasound, followed by endoscopic retrograde cholangiopancreatography and/or percutaneous cholangiography in 3 cases.
  • Radiological findings included common hepatic duct complete obstruction in 1 case, common hepatic duct stenosis in 2 cases, common bile duct obstruction in 1 case, and intrahepatic bile ducts dilation without a well-recognized obstruction in 1 case.
  • The present series suggests that in some patients receiving hepatic arterial infusion of floxuridine extrahepatic biliary stenosis may represent the primary event leading to a secondary intrahepatic biliary damage that does not correlate with specific floxuridine toxicity but results from bile stasis and infection, recurrent cholangitis and eventually biliary sclerosis.
  • Aggressive research for extrahepatic biliary sclerosis is advised, since an early nonsurgical treatment of extrahepatic biliary stenosis may prevent an irreversible intrahepatic biliary sclerosis worsening the prognosis of metastatic liver disease.
  • [MeSH-major] Adenocarcinoma / secondary. Cholestasis, Extrahepatic / chemically induced. Colorectal Neoplasms / drug therapy. Floxuridine / adverse effects. Infusions, Intra-Arterial. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Cholangiography. Cholangitis, Sclerosing / chemically induced. Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / therapy. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Liver Function Tests. Male. Middle Aged. Stents


11. Dubaniewicz A, Dubaniewicz A: [Cholangiocarcinoma--bile ducts cancer]. Wiad Lek; 2003;56(1-2):57-60
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cholangiocarcinoma--bile ducts cancer].
  • Cholangiocarcinoma (CC) is a malignant neoplasm deriving from intra- and extrahepatic bile ducts.
  • CC often causes symptoms by blocking the bile ducts, abdominal pain, weight loss, signs of portal hypertension, rare ascites and thrombophlebitis.
  • Recently, FDG positron emission tomography has been suggested to be a sensitive technique in identifying small bile duct cancers.
  • The adjuvant radio- and chemotherapy and transplantation are not satisfactory.
  • Palliative therapy includes surgical biliary-intestinal bypass procedures as well as operative and nonoperative techniques for biliary intestinal drainage.
  • Recently, the local treatment of CC by photodynamic therapy as a palliative strategy is very promising.
  • Post resection 5-year survival is affirmed in about 25% of CC, whereas after palliative treatment only 1 year.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cholangiocarcinoma
  • [MeSH-minor] Adenocarcinoma / complications. Bile Ducts / pathology. Biomarkers, Tumor / analysis. Hepatitis, Chronic / complications. Humans. Liver / pathology. Palliative Care. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12901270.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


12. Jarnagin WR, Shoup M: Surgical management of cholangiocarcinoma. Semin Liver Dis; 2004 May;24(2):189-99
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary tract cancer affects approximately 7500 Americans each year.
  • Tumors arising from the gallbladder are the most common; those of bile duct origin, or cholangiocarcinoma, are less frequently encountered, constituting approximately 2% of all reported cancers.
  • Twenty to 30% of cholangiocarcinomas originate in the lower bile duct, and approximately 10% arise within the intrahepatic biliary tree and will present as an intrahepatic mass.
  • Complete resection remains the most effective and only potentially curative therapy for cholangiocarcinoma.
  • Distal cholangiocarcinomas, on the other hand, are treated like all periampullary malignancies and typically require pancreaticoduodenectomy.
  • Most patients with cholangiocarcinoma present with advanced disease that is not amenable to surgical treatment, and even with a complete resection, recurrence rates are high.
  • Adjuvant therapy (chemotherapy and radiation therapy) has not been shown clearly to reduce recurrence risk.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Bile Ducts, Extrahepatic / surgery. Bile Ducts, Intrahepatic / surgery. Hepatectomy. Humans. Neoplasm Staging. Palliative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15192791.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


13. Saikusa N, Naito S, Iinuma Y, Ohtani T, Yokoyama N, Nitta K: Invasive cholangiocarcinoma identified in congenital biliary dilatation in a 3-year-old boy. J Pediatr Surg; 2009 Nov;44(11):2202-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and magnetic resonance imaging demonstrated a dilated extrahepatic bile duct.
  • A diagnosis of Todani's type 1a CBD was made.
  • Intraoperative cholangiography demonstrated the presence of pancreaticobiliary maljunction but could not reveal any tumor lesion in the bile duct.
  • The excision of extrahepatic bile duct and gallbladder and Roux-en-Y hepaticojejunostomy were performed.
  • However, the postoperative histopathologic examinations confirmed the presence of well-differentiated tubular adenocarcinoma with lymphovascular invasion.
  • Most of the carcinoma remained within the mucosal layer, and the carcinoma was identified at both the distal and proximal surgical margins of the bile duct.
  • A close follow-up with abdominal computed tomography has been going on without either additional surgery or adjuvant chemotherapy about for 1 year.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Common Bile Duct / pathology. Common Bile Duct / surgery. Dilatation, Pathologic / congenital. Dilatation, Pathologic / surgery
  • [MeSH-minor] Age Factors. Anastomosis, Roux-en-Y / methods. Bile Ducts, Extrahepatic / radiography. Bile Ducts, Extrahepatic / surgery. Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures / methods. Child, Preschool. Cholangiography. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / radiography. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944233.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Maire F, Hammel P, Ponsot P, Aubert A, O'Toole D, Hentic O, Levy P, Ruszniewski P: Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol; 2006 Apr;101(4):735-42
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.
  • BACKGROUND: Life expectancy in patients with unresectable pancreatic cancer has improved by using new chemotherapeutic regimens.
  • AIM: To evaluate the incidence of biliary and duodenal stenoses as well as technical success and short- and long-term patency of endoscopically deployed stents in patients with unresectable pancreatic cancer.
  • PATIENTS AND METHODS: All consecutive patients with unresectable cancer of the pancreatic head seen between January 1999 and September 2003 in our center were retrospectively studied.
  • Patients with biliary and/or duodenal stenoses underwent endoscopic stent insertion as first intention therapy.
  • RESULTS: One hundred patients, median age 65 yr (32-85), with locally advanced (62%) or metastatic (38%) pancreatic cancer were studied.
  • Eighty-three percent received at least one line of chemotherapy.
  • In the 23 patients who developed both biliary and duodenal stenoses, combined stenting was successful in 91% of cases.
  • No major complication or death occurred related to endoscopic treatment.
  • CONCLUSION: Endoscopic palliative treatment of both biliary and duodenal stenoses is safe and effective in the long term, including in patients with combined obstructions.
  • [MeSH-major] Adenocarcinoma / complications. Biliary Tract. Cholestasis, Extrahepatic / therapy. Duodenal Obstruction / therapy. Duodenum. Palliative Care. Pancreatic Neoplasms / complications. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct Diseases / etiology. Common Bile Duct Diseases / therapy. Endoscopy. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2006 Apr;101(4):743-5 [16635222.001]
  • (PMID = 16635221.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Asakura H, Ohtsuka M, Ito H, Kimura F, Ambiru S, Shimizu H, Togawa A, Yoshidome H, Kato A, Miyazaki M: Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology; 2005 May-Jun;52(63):722-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old man underwent extended left hepatic lobectomy with caudate lobe resection, extrahepatic bile duct resection, portal vein resection and reconstruction, and middle hepatic vein resection and reconstruction with lymph node dissection for a liver tumor that was located in the caudate lobe.
  • Histological examination of the resected specimen revealed moderately differentiated adenocarcinoma compatible with cholangiocarcinoma, and lymph node metastases were found in the area of the hepatoduodenal ligament and the paraaortic region.
  • These recurrent tumors were completely eliminated by systemic chemotherapy with cisplatin or mitomycin C.
  • The patient is now doing well 6 years and 5 months after surgical treatment.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Hepatectomy. Lymph Node Excision. Lymphatic Metastasis / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retreatment

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966191.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


16. Fujisaki S, Takayama T, Takashina M, Kayashima S, Tomita R, Oimuna T, Nemoto N: [Experience of gemcitabine therapy after non-curative resection for biliary tract cancer]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1351-3
Genetic Alliance. consumer health - Biliary Tract Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of gemcitabine therapy after non-curative resection for biliary tract cancer].
  • We report a patient in which gemcitabine therapy was effective for controlling relapse of cancer after noncurative resection for bile duct cancer.
  • A 75-year-old man suffering from bile duct cancer underwent resection of extrahepatic bile duct on December 3, 2002, but surgical margins were positive at the hepatic site and the pancreatic site.
  • Two months after surgery, he began to undergo gemcitabine therapy (1,000 mg/body, biweekly) as adjuvant chemotherapy in the outpatient clinic.
  • The chemotherapy has been continued up to the present.
  • No severe side effect has been observed throughout the treatment.
  • The patient remains well with no evidence of relapse of the cancer 26 months after surgery.
  • Gemcitabine therapy is considered effective as adjuvant chemotherapy for bile duct cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Aged. Bile Ducts, Intrahepatic / surgery. Chemotherapy, Adjuvant. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184940.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


17. Shafizadeh N, Grenert JP, Sahai V, Kakar S: Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol; 2010 Apr;41(4):485-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Standard chemotherapy often offers minimal benefit.
  • Fifty-one formalin-fixed, paraffin-embedded cases of adenocarcinomas (26 intrahepatic, 19 extrahepatic, 6 gallbladder) were stained with monoclonal antibodies against epidermal growth factor receptor and HER-2/neu.
  • [MeSH-major] Adenocarcinoma / metabolism. Bile Duct Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. Gallbladder Neoplasms / metabolism. Gallbladder Neoplasms / pathology. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20040392.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


18. Karakolios A, Kasapis C, Kallinikidis T, Kalpidis P, Grigoriadis N: Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol; 2003 Nov;1(6):480-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.
  • Malignancies may cause cholestatic jaundice through well-recognized mechanisms (e.g., bile duct obstruction or widespread hepatic infiltration).
  • Prostate cancer presenting initially with cholestatic jaundice without any obvious cause (i.e., obstruction or infiltration) has been reported in 2 cases in the medical literature.
  • During the diagnostic work-up, prostate cancer was diagnosed.
  • The results of appropriate investigations performed during the patient's hospitalizations indicated no evidence of hepatic metastases or extrahepatic biliary obstruction.
  • After treatment with flutamide and leuprolide, the patient's symptoms and the laboratory abnormalities reversed rapidly.
  • Patients with unexplained cholestasis should be investigated for malignancies, including prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Jaundice, Obstructive / diagnosis. Paraneoplastic Syndromes / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Alkaline Phosphatase / metabolism. Antineoplastic Agents, Hormonal / therapeutic use. Bilirubin / metabolism. Biomarkers, Tumor / analysis. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Flutamide / therapeutic use. Humans. Leuprolide / therapeutic use. Male. Pruritus / diagnosis. Pruritus / drug therapy. Pruritus / metabolism. Tomography, X-Ray Computed. Transaminases / metabolism. gamma-Glutamyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017648.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 76W6J0943E / Flutamide; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.- / Transaminases; EC 3.1.3.1 / Alkaline Phosphatase; EFY6W0M8TG / Leuprolide; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


19. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A: S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol; 2008 Oct;62(5):849-55
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.
  • A pilot phase II study showed S-1 monotherapy to be safe and active against biliary tract cancer (BTC).
  • We, therefore, conducted a multicenter phase II study to evaluate the antitumor effect and safety of S-1 in previously untreated patients with advanced BTC.
  • Eligible patients had pathologically proven, unresectable adenocarcinoma with no prior chemotherapy or radiotherapy.
  • The primary tumor sites were as follows: gallbladder (n = 20), extrahepatic bile duct (n = 15), and the ampulla of Vater (n = 5).
  • The median overall survival (median OS) was 9.4 months, and the median time to progression was 3.7 months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Biliary Tract Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Combinations. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18214482.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down






Advertisement